Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park Y.H. | - |
dc.contributor.author | Kim T.-Y. | - |
dc.contributor.author | Kim G.M. | - |
dc.contributor.author | Kang S.Y. | - |
dc.contributor.author | Park I.H. | - |
dc.contributor.author | Kim J.H. | - |
dc.contributor.author | Lee K.E. | - |
dc.contributor.author | Ahn H.K. | - |
dc.contributor.author | Lee M.H. | - |
dc.contributor.author | Kim H.-J. | - |
dc.contributor.author | Kim H.J. | - |
dc.contributor.author | Lee J.I. | - |
dc.contributor.author | Koh S.-J. | - |
dc.contributor.author | Kim J.-Y. | - |
dc.contributor.author | Lee K.-H. | - |
dc.contributor.author | Sohn J. | - |
dc.contributor.author | Kim S.-B. | - |
dc.contributor.author | Ahn J.-S. | - |
dc.contributor.author | Im Y.-H. | - |
dc.contributor.author | Jung K.H. | - |
dc.contributor.author | Im S.-A. | - |
dc.contributor.author | Ahn H.K. | - |
dc.contributor.author | Cho E.K. | - |
dc.contributor.author | Park I.H. | - |
dc.contributor.author | Lee K.S. | - |
dc.contributor.author | Sim S.S. | - |
dc.contributor.author | Hong S.J. | - |
dc.contributor.author | Chang M.H. | - |
dc.contributor.author | Kim J.H. | - |
dc.contributor.author | Kim Y.J. | - |
dc.contributor.author | Kim S.H. | - |
dc.contributor.author | Suh K.J. | - |
dc.contributor.author | Park Y.H. | - |
dc.contributor.author | Park W.Y. | - |
dc.contributor.author | Choi Y.L. | - |
dc.contributor.author | Yu J.H. | - |
dc.contributor.author | Im Y.H. | - |
dc.contributor.author | Ahn J.S. | - |
dc.contributor.author | Hur J.Y. | - |
dc.contributor.author | Park S.H. | - |
dc.contributor.author | Kim J.Y. | - |
dc.contributor.author | Nam S.J. | - |
dc.contributor.author | Lee J.E. | - |
dc.contributor.author | Kim S.W. | - |
dc.contributor.author | Lee S.K. | - |
dc.contributor.author | Im S.A. | - |
dc.contributor.author | Kim M.S. | - |
dc.contributor.author | Kim T.Y. | - |
dc.contributor.author | Oh D.Y. | - |
dc.contributor.author | Lee K.H. | - |
dc.contributor.author | Lee D.W. | - |
dc.contributor.author | Kim H.J. | - |
dc.contributor.author | Jung K.H. | - |
dc.contributor.author | Kim S.B. | - |
dc.contributor.author | Ahn J.H. | - |
dc.contributor.author | Kim J.E. | - |
dc.contributor.author | Jung J.H. | - |
dc.contributor.author | Kang S.Y. | - |
dc.contributor.author | Ahn M.S. | - |
dc.contributor.author | Choi Y.W. | - |
dc.contributor.author | Kim G.M. | - |
dc.contributor.author | Sohn J.H. | - |
dc.contributor.author | Kim M.H. | - |
dc.contributor.author | Koh S.J. | - |
dc.contributor.author | Cheon J.K. | - |
dc.contributor.author | Lee J.I. | - |
dc.contributor.author | Lim S.T. | - |
dc.contributor.author | Hyun S.Y. | - |
dc.contributor.author | Lee K.E. | - |
dc.contributor.author | Lee M.H. | - |
dc.contributor.author | Cho J.H. | - |
dc.contributor.author | Lim J.H. | - |
dc.date.accessioned | 2021-05-13T00:40:07Z | - |
dc.date.available | 2021-05-13T00:40:07Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 1470-2045 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80991 | - |
dc.description.abstract | Background: Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: This multicentre, open-label, randomised, phase 2 study was done in 14 academic institutions in South Korea. Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0–2 were included. One line of previous chemotherapy for metastatic breast cancer was allowed. Patients were randomly assigned, using a random permuted block design (with a block size of two), to receive palbociclib plus combination endocrine therapy (oral exemestane 25 mg per day for 28 days and oral palbociclib 125 mg per day for 21 days every 4 weeks plus leuprolide 3·75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1250 mg/m | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.isPartOf | LANCET ONCOLOGY | - |
dc.title | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000500750400055 | - |
dc.identifier.doi | 10.1016/S1470-2045(19)30565-0 | - |
dc.identifier.bibliographicCitation | LANCET ONCOLOGY, v.20, no.12, pp.1750 - 1759 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85075681308 | - |
dc.citation.endPage | 1759 | - |
dc.citation.startPage | 1750 | - |
dc.citation.title | LANCET ONCOLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Cho E.K. | - |
dc.subject.keywordAuthor | ENDOCRINE THERAPY | - |
dc.subject.keywordAuthor | DOUBLE-BLIND | - |
dc.subject.keywordAuthor | PATTERNS | - |
dc.subject.keywordAuthor | CHEMOTHERAPY | - |
dc.subject.keywordAuthor | FULVESTRANT | - |
dc.subject.keywordAuthor | PLACEBO | - |
dc.subject.keywordAuthor | EUROPE | - |
dc.subject.keywordAuthor | TUMORS | - |
dc.subject.keywordPlus | ENDOCRINE THERAPY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | FULVESTRANT | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | EUROPE | - |
dc.subject.keywordPlus | TUMORS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.